Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2017 / Mar / Cracking the Case of Crohn’s
Microbiology & Immunology Microbiology and Immunology Clinical care Omics Molecular Pathology

Cracking the Case of Crohn’s

NAPPA, a novel profiling system for Crohn's disease, offers a new diagnostic test and more insight into the disease

By William Aryitey 03/24/2017 1 min read

Share

Abdominal pain, diarrhea, anemia, weight loss... all symptoms of Crohn’s disease. But the cause? It has eluded pathologists and clinicians since the illness was first described over a century ago. Now, researchers at Arizona State University and the Mayo Clinic have teamed up to create an autoantibody biomarker panel for the condition (1) – one that may not only help unveil new diagnostics for the condition, but possibly even pave the way to discovering its roots.

“There are currently no gold standard tests for the diagnosis and prognosis of Crohn’s disease,” says Joshua LaBaer, Director of the Biodesign Institute at Arizona State University. “Delay in diagnosis – and misdiagnosis – postpones the initiation of appropriate treatment, and there is also a lack of means to distinguish between patients with aggressive or non-aggressive forms of the disease.” The current de facto methods of identifying the immunological disorder involve expensive equipment (MRI) or invasive surgical procedures (biopsy). The investigators believed there had to be a better way to serve patients and began searching for an efficient, noninvasive clinical tool to diagnose Crohn’s disease. The result? A novel system called NAPPA – nucleic acid programmable protein arrays – that profiles Crohn’s-associated autoantibodies against more than 1,900 blood-borne human proteins. After further validation by an ELISA, their results revealed a panel of IgA antibodies that could be used as a diagnostic test for Crohn’s disease.

It’s one of the first investigations to explore the immuno-proteomics of the disease, and the researchers are optimistic that the approach may shine a light on its cause. Moreover, the array can also be applied to other illnesses; LaBaer says, “We have already applied NAPPA in the study of many other diseases involving autoimmunity (type 1 diabetes, rheumatoid arthritis), cancers (breast and lung), neurodegeneration (Alzheimer’s disease), and infectious disease (tuberculosis).” “We hope our pilot study in Crohn’s disease will serve as a springboard to allow us to carry out a more comprehensive study,” says LaBaer, who hopes it will eventually lead to a product that can improve clinical management of patients.

Newsletters

Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. H Wang et al., “Identification of antibody against SNRPB, small nuclear ribonucleoprotein-associated proteins B and B’, ad an autoantibody marker in Crohn’s disease using an immunoproteomics approach”, J Crohns Colitis, [Epub ahead of print] (2017). PMID: 28204086.

About the Author(s)

William Aryitey

My fascination with science, gaming, and writing led to my studying biology at university, while simultaneously working as an online games journalist. After university, I travelled across Europe, working on a novel and developing a game, before finding my way to Texere. As Associate Editor, I’m evolving my loves of science and writing, while continuing to pursue my passion for gaming and creative writing in a personal capacity.

More Articles by William Aryitey

Explore More in Analytical Science

Dive deeper into the analytical science. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Context Matters in Cancer Biology
Microbiology and Immunology
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

What’s New in Infectious Disease? (December 2021)
Microbiology and Immunology
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

Immunology Insights
Microbiology and Immunology
Immunology Insights

January 13, 2022

1 min read

The latest research in pathology and laboratory medicine

2021: A Laboratory Medicine Roundup
Microbiology and Immunology
2021: A Laboratory Medicine Roundup

January 18, 2022

3 min read

From transgender health care to the power of pathology podcasts, we take a look at our most popular articles of the last year

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.